{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:25:59Z","timestamp":1779906359655,"version":"3.53.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001325","name":"Cancer Association of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>New biomarkers are urgently needed to detect pancreatic ductal adenocarcinoma (PDAC) at an earlier stage for individualized treatment strategies and to improve outcomes. Autoantibodies (AAbs) in principle make attractive biomarkers as they arise early in disease, report on disease-associated perturbations in cellular proteomes, and are static in response to other common stimuli, yet are measurable in the periphery, potentially well in advance of the onset of clinical symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we used high-throughput, custom cancer antigen microarrays to identify a clinically relevant autoantibody biomarker combination able to differentially detect PDAC. Specifically, we quantified the serological AAb profiles of 94 PDAC, chronic pancreatitis (CP), other pancreatic- (PC) and prostate cancers (PRC), non-ulcer dyspepsia patients (DYS), and healthy controls (HC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Combinatorial ROC curve analysis on the training cohort data from the cancer antigen microarrays identified the most effective biomarker combination as CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85\u00b70% (SE = 0\u00b7828, SP = 0\u00b7684). Additionally, differential expression analysis on the samples run on the iOme\u2122 array identified 4 biomarkers (ALX1-GPA33-LIP1-SUB1) upregulated in PDAC against diseased and healthy controls. Identified AAbs were validated in silico using public immunohistochemistry datasets and experimentally using a custom PDAC protein microarray comprising the 11 optimal AAb biomarker panel. The clinical utility of the biomarker panel was tested in an independent cohort comprising 223 PDAC, PC, PRC, colorectal cancer (CRC), and HC samples. Combinatorial ROC curve analysis on the validation data identified the most effective biomarker combination to be CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85\u00b70% (SE = 0\u00b7828, SP = 0\u00b7684). Subsequently, the specificity of the 11-biomarker panel was validated against other cancers (PDAC vs PC: AUC = 70\u00b73%; PDAC vs CRC: AUC = 84\u00b73%; PDAC vs PRC: AUC = 80\u00b72%) and healthy controls (PDAC vs HC: AUC = 80\u00b79%), confirming that this novel AAb biomarker panel is able to selectively detect PDAC amongst other confounding diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This AAb panel may therefore have the potential to form the basis of a novel diagnostic test for PDAC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1494446","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:26:40Z","timestamp":1738218400000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Metoboroghene O.","family":"Mowoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Nqada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urda","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo","family":"Kloppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suba","family":"Dharshanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafirah","family":"Azween","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Maimela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1990.01410140108018","article-title":"Preoperative staging and assessment of resectability of pancreatic cancer","volume":"125","author":"Warshaw","year":"1990","journal-title":"Arch Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e01055","article-title":"Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype","volume":"4","author":"Swayden","year":"2018","journal-title":"Heliyon"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004215","article-title":"It can't be very important because it comes and goes\"\u2013patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study","volume":"4","author":"Evans","year":"2014","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/cancers9050042","article-title":"KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer","volume":"9","author":"Cicenas","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/pin.2014.64.issue-1","article-title":"Molecular pathology of pancreatic cancer","volume":"64","author":"Saiki","year":"2014","journal-title":"Pathol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13193-011-0042-1","article-title":"Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review","volume":"2","author":"Ballehaninna","year":"2011","journal-title":"Indian J Surg Oncol"},{"key":"B9","first-page":"189","article-title":"Carbohydrate antigen sialyl Lewis a\u2013its pathophysiological significance and induction mechanism in cancer progression","volume":"30","author":"Kannagi","year":"2007","journal-title":"Chang Gung Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00006676-198707000-00006","article-title":"High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings","volume":"2","author":"Safi","year":"1987","journal-title":"Pancreas"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-015-2923-z","article-title":"Initial misdiagnosis of proximal pancreatic adenocarcinoma is associated with delay in diagnosis and advanced stage at presentation","volume":"19","author":"Swords","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M700072-MCP200","article-title":"Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer","volume":"6","author":"Chen","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cancers10010006","article-title":"Immune evasion in pancreatic cancer: from mechanisms to therapy","volume":"10","author":"Martinez-Bosch","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200300722","article-title":"Functional protein microarrays for parallel characterisation of p53 mutants","volume":"4","author":"Boutell","year":"2004","journal-title":"PROTEOMICS"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i12","article-title":"Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort","volume":"7","author":"Adeola","year":"2016","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28832","article-title":"Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens","volume":"135","author":"Beeton-Kempen","year":"2014","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-61779-286-1_21","article-title":"Protein function microarrays for customised systems-oriented proteome analysis","volume":"785","author":"Blackburn","year":"2011","journal-title":"Methods Mol Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-022-05095-x","article-title":"Pro-MAP: a robust pipeline for the pre-processing of single channel protein microarray data","volume":"23","author":"Mowoe","year":"2022","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"45477","DOI":"10.1038\/srep45477","article-title":"CombiROC: an interactive web tool for selecting accurate marker combinations of omics data","volume":"7","author":"Mazzara","year":"2017","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol Biosyst"},{"key":"B24","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Hadley","year":"2016"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.603837","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv037","article-title":"Metabolic reprogramming and dysregulated metabolism: cause, consequence and\/or enabler of environmental carcinogenesis","author":"Robey","year":"2015","journal-title":"Carcinogenesis"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/978-3-030-65768-0_5","article-title":"The intricate metabolism of pancreatic cancers","volume-title":"The Heterogeneity of Cancer Metabolism. Advances in Experimental Medicine and Biology","author":"Camelo","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12967-024-05598-6","article-title":"Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells","volume":"22","author":"Mascaraque","year":"2024","journal-title":"J Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1091801","article-title":"Amoeboid migration in health and disease: Immune responses versus cancer dissemination","volume":"10","author":"George","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v112.8","article-title":"Regulation of vascular permeability in cancer metastasis","volume":"112","author":"Tomita","year":"2021","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00102.x","article-title":"Invasive human pancreatic carcinoma cells adhere to endothelial tri-cellular corners and increase endothelial permeability","volume":"96","author":"Nakai","year":"2005","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"117936","DOI":"10.1016\/j.lfs.2020.117936","article-title":"The Ras-ERK1\/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.148","article-title":"Tumour cell survival signalling by the ERK1\/2 pathway","volume":"16","author":"Balmanno","year":"2009","journal-title":"Cell Death Differentiation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.s23","article-title":"HER2 as a prognostic and predictive marker for breast cancer","volume":"12","author":"Cooke","year":"2001","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000101","article-title":"Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers","volume":"39","author":"Park","year":"2016","journal-title":"J Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1494446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:26:44Z","timestamp":1738218404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1494446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1494446"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1494446","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"article-number":"1494446"}}